Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy
Identifieur interne : 005727 ( Main/Merge ); précédent : 005726; suivant : 005728Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy
Auteurs : Dirk Dressler [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-03.
English descriptors
- KwdEn :
- Action Potentials (drug effects), Animals, Anti-Dyskinesia Agents (immunology), Anti-Dyskinesia Agents (therapeutic use), Antibodies (immunology), Antibody Formation (drug effects), Antibody Formation (physiology), Botulinum Toxins (immunology), Botulinum Toxins (therapeutic use), Dose-Response Relationship, Drug, Drug Administration Schedule, Electromyography, Enzyme-Linked Immunosorbent Assay (methods), Humans, Muscles (drug effects), Reaction Time, Time Factors, Torticollis (drug therapy), Torticollis (physiopathology), Treatment Failure, antibodies, antibody testing, botulinum toxin, clinical features, prevention, therapy failure.
- MESH :
- chemical , immunology : Anti-Dyskinesia Agents, Antibodies, Botulinum Toxins.
- drug effects : Action Potentials, Antibody Formation, Muscles.
- drug therapy : Torticollis.
- methods : Enzyme-Linked Immunosorbent Assay.
- physiology : Antibody Formation.
- physiopathology : Torticollis.
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- Animals, Dose-Response Relationship, Drug, Drug Administration Schedule, Electromyography, Humans, Reaction Time, Time Factors, Treatment Failure.
Abstract
Therapy with botulinum toxin (BT) can fail due to numerous reasons, including failure due to formation of antibodies against BT (BT‐AB, AB‐TF). AB‐TF is a secondary therapy failure, i.e. it occurs during the course of an ongoing BT therapy. It can be subjective or objective, temporary or permanent, and partial or complete. Complete AB‐TF is usually preceded by injection series with partial AB‐TF in which the therapeutic effect is reduced in its intensity and duration. AB‐TF usually occurs within 2 or 3 years after initiation of BT therapy. After 4 years it is rare. BT‐AB are neutralising or blocking by definition, i.e. they are directly interfering with BT's biological mechanism of action. Non‐neutralizing or non‐blocking antibodies occur. BT‐AB can be detected by the mouse diaphragm assay, the mouse protection assay, and by patient‐based tests such as the sternocleidomastoid test, the extensor digitorum brevis test, and the frowning test. Enzyme‐linked immunosorbent assays (ELISA) have a low specificity and a low sensitivity for detection of BT‐AB. BT‐AB titres drop spontaneously after cessation of BT therapy but latencies are too long to be compatible with an effective BT therapy. BT dosage increase can be successful to overcome AB‐TF when AB‐TF is partial and when BT‐AB titres are low. Usage of alternative BT type A preparations fail to overcome AB‐TF. Alternative BT types, such as BT type B and BT type F, are initially successful in AB‐TF, but stimulate formation of antibodies against the alternative BT types after few applications. BT‐AB reduction with immunosuppressants and inactivation of BT‐AB by intravenous immunoglobuline application has not yet been achieved. Extraction of BT‐AB by plasmapheresis and immunoadsorption is possible but is associated with substantial logistic problems. Prevention of BT‐AB formation, therefore, is of paramount importance. Identified risk factors for BT‐AB formation must be taken into account when BT therapy is planned. The most interesting perspective seems to be the development of new BT preparations with reduced antigenicity. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20022
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000062
- to stream Istex, to step Curation: 000062
- to stream Istex, to step Checkpoint: 002750
- to stream PubMed, to step Corpus: 003507
- to stream PubMed, to step Curation: 003507
- to stream PubMed, to step Checkpoint: 003517
- to stream Ncbi, to step Merge: 000D77
- to stream Ncbi, to step Curation: 000D77
- to stream Ncbi, to step Checkpoint: 000D77
Links to Exploration step
ISTEX:7E1934980910F60F68521285C7890F73746B2F38Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy</title>
<author><name sortKey="Dressler, Dirk" sort="Dressler, Dirk" uniqKey="Dressler D" first="Dirk" last="Dressler">Dirk Dressler</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7E1934980910F60F68521285C7890F73746B2F38</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.20022</idno>
<idno type="url">https://api.istex.fr/document/7E1934980910F60F68521285C7890F73746B2F38/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000062</idno>
<idno type="wicri:Area/Istex/Curation">000062</idno>
<idno type="wicri:Area/Istex/Checkpoint">002750</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Dressler D:clinical:presentation:and</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15027060</idno>
<idno type="wicri:Area/PubMed/Corpus">003507</idno>
<idno type="wicri:Area/PubMed/Curation">003507</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003517</idno>
<idno type="wicri:Area/Ncbi/Merge">000D77</idno>
<idno type="wicri:Area/Ncbi/Curation">000D77</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000D77</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Dressler D:clinical:presentation:and</idno>
<idno type="wicri:Area/Main/Merge">005727</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy</title>
<author><name sortKey="Dressler, Dirk" sort="Dressler, Dirk" uniqKey="Dressler D" first="Dirk" last="Dressler">Dirk Dressler</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Rostock University, Rostock</wicri:regionArea>
<wicri:noRegion>Rostock</wicri:noRegion>
<wicri:noRegion>Rostock</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-03">2004-03</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">S8</biblScope>
<biblScope unit="page" from="S92">S92</biblScope>
<biblScope unit="page" to="S100">S100</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">7E1934980910F60F68521285C7890F73746B2F38</idno>
<idno type="DOI">10.1002/mds.20022</idno>
<idno type="ArticleID">MDS20022</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Action Potentials (drug effects)</term>
<term>Animals</term>
<term>Anti-Dyskinesia Agents (immunology)</term>
<term>Anti-Dyskinesia Agents (therapeutic use)</term>
<term>Antibodies (immunology)</term>
<term>Antibody Formation (drug effects)</term>
<term>Antibody Formation (physiology)</term>
<term>Botulinum Toxins (immunology)</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Electromyography</term>
<term>Enzyme-Linked Immunosorbent Assay (methods)</term>
<term>Humans</term>
<term>Muscles (drug effects)</term>
<term>Reaction Time</term>
<term>Time Factors</term>
<term>Torticollis (drug therapy)</term>
<term>Torticollis (physiopathology)</term>
<term>Treatment Failure</term>
<term>antibodies</term>
<term>antibody testing</term>
<term>botulinum toxin</term>
<term>clinical features</term>
<term>prevention</term>
<term>therapy failure</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Antibodies</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Action Potentials</term>
<term>Antibody Formation</term>
<term>Muscles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Enzyme-Linked Immunosorbent Assay</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Antibody Formation</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Electromyography</term>
<term>Humans</term>
<term>Reaction Time</term>
<term>Time Factors</term>
<term>Treatment Failure</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Therapy with botulinum toxin (BT) can fail due to numerous reasons, including failure due to formation of antibodies against BT (BT‐AB, AB‐TF). AB‐TF is a secondary therapy failure, i.e. it occurs during the course of an ongoing BT therapy. It can be subjective or objective, temporary or permanent, and partial or complete. Complete AB‐TF is usually preceded by injection series with partial AB‐TF in which the therapeutic effect is reduced in its intensity and duration. AB‐TF usually occurs within 2 or 3 years after initiation of BT therapy. After 4 years it is rare. BT‐AB are neutralising or blocking by definition, i.e. they are directly interfering with BT's biological mechanism of action. Non‐neutralizing or non‐blocking antibodies occur. BT‐AB can be detected by the mouse diaphragm assay, the mouse protection assay, and by patient‐based tests such as the sternocleidomastoid test, the extensor digitorum brevis test, and the frowning test. Enzyme‐linked immunosorbent assays (ELISA) have a low specificity and a low sensitivity for detection of BT‐AB. BT‐AB titres drop spontaneously after cessation of BT therapy but latencies are too long to be compatible with an effective BT therapy. BT dosage increase can be successful to overcome AB‐TF when AB‐TF is partial and when BT‐AB titres are low. Usage of alternative BT type A preparations fail to overcome AB‐TF. Alternative BT types, such as BT type B and BT type F, are initially successful in AB‐TF, but stimulate formation of antibodies against the alternative BT types after few applications. BT‐AB reduction with immunosuppressants and inactivation of BT‐AB by intravenous immunoglobuline application has not yet been achieved. Extraction of BT‐AB by plasmapheresis and immunoadsorption is possible but is associated with substantial logistic problems. Prevention of BT‐AB formation, therefore, is of paramount importance. Identified risk factors for BT‐AB formation must be taken into account when BT therapy is planned. The most interesting perspective seems to be the development of new BT preparations with reduced antigenicity. © 2004 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.20022"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy</title>
<author><name sortKey="Dressler, Dirk" sort="Dressler, Dirk" uniqKey="Dressler D" first="Dirk" last="Dressler">Dirk Dressler</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7E1934980910F60F68521285C7890F73746B2F38</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.20022</idno>
<idno type="url">https://api.istex.fr/document/7E1934980910F60F68521285C7890F73746B2F38/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000062</idno>
<idno type="wicri:Area/Istex/Curation">000062</idno>
<idno type="wicri:Area/Istex/Checkpoint">002750</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Dressler D:clinical:presentation:and</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy</title>
<author><name sortKey="Dressler, Dirk" sort="Dressler, Dirk" uniqKey="Dressler D" first="Dirk" last="Dressler">Dirk Dressler</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Rostock University, Rostock</wicri:regionArea>
<wicri:noRegion>Rostock</wicri:noRegion>
<wicri:noRegion>Rostock</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-03">2004-03</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">S8</biblScope>
<biblScope unit="page" from="S92">S92</biblScope>
<biblScope unit="page" to="S100">S100</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">7E1934980910F60F68521285C7890F73746B2F38</idno>
<idno type="DOI">10.1002/mds.20022</idno>
<idno type="ArticleID">MDS20022</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>antibodies</term>
<term>antibody testing</term>
<term>botulinum toxin</term>
<term>clinical features</term>
<term>prevention</term>
<term>therapy failure</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Therapy with botulinum toxin (BT) can fail due to numerous reasons, including failure due to formation of antibodies against BT (BT‐AB, AB‐TF). AB‐TF is a secondary therapy failure, i.e. it occurs during the course of an ongoing BT therapy. It can be subjective or objective, temporary or permanent, and partial or complete. Complete AB‐TF is usually preceded by injection series with partial AB‐TF in which the therapeutic effect is reduced in its intensity and duration. AB‐TF usually occurs within 2 or 3 years after initiation of BT therapy. After 4 years it is rare. BT‐AB are neutralising or blocking by definition, i.e. they are directly interfering with BT's biological mechanism of action. Non‐neutralizing or non‐blocking antibodies occur. BT‐AB can be detected by the mouse diaphragm assay, the mouse protection assay, and by patient‐based tests such as the sternocleidomastoid test, the extensor digitorum brevis test, and the frowning test. Enzyme‐linked immunosorbent assays (ELISA) have a low specificity and a low sensitivity for detection of BT‐AB. BT‐AB titres drop spontaneously after cessation of BT therapy but latencies are too long to be compatible with an effective BT therapy. BT dosage increase can be successful to overcome AB‐TF when AB‐TF is partial and when BT‐AB titres are low. Usage of alternative BT type A preparations fail to overcome AB‐TF. Alternative BT types, such as BT type B and BT type F, are initially successful in AB‐TF, but stimulate formation of antibodies against the alternative BT types after few applications. BT‐AB reduction with immunosuppressants and inactivation of BT‐AB by intravenous immunoglobuline application has not yet been achieved. Extraction of BT‐AB by plasmapheresis and immunoadsorption is possible but is associated with substantial logistic problems. Prevention of BT‐AB formation, therefore, is of paramount importance. Identified risk factors for BT‐AB formation must be taken into account when BT therapy is planned. The most interesting perspective seems to be the development of new BT preparations with reduced antigenicity. © 2004 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.</title>
<author><name sortKey="Dressler, Dirk" sort="Dressler, Dirk" uniqKey="Dressler D" first="Dirk" last="Dressler">Dirk Dressler</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Rostock University, Rostock, Germany. dirk.dressler@med.uni-rostock.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Rostock University, Rostock</wicri:regionArea>
<wicri:noRegion>Rostock</wicri:noRegion>
<wicri:noRegion>Rostock</wicri:noRegion>
<wicri:noRegion>Rostock</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15027060</idno>
<idno type="pmid">15027060</idno>
<idno type="doi">10.1002/mds.20022</idno>
<idno type="wicri:Area/PubMed/Corpus">003507</idno>
<idno type="wicri:Area/PubMed/Curation">003507</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003517</idno>
<idno type="wicri:Area/Ncbi/Merge">000D77</idno>
<idno type="wicri:Area/Ncbi/Curation">000D77</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000D77</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Dressler D:clinical:presentation:and</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.</title>
<author><name sortKey="Dressler, Dirk" sort="Dressler, Dirk" uniqKey="Dressler D" first="Dirk" last="Dressler">Dirk Dressler</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Rostock University, Rostock, Germany. dirk.dressler@med.uni-rostock.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Rostock University, Rostock</wicri:regionArea>
<wicri:noRegion>Rostock</wicri:noRegion>
<wicri:noRegion>Rostock</wicri:noRegion>
<wicri:noRegion>Rostock</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Action Potentials (drug effects)</term>
<term>Animals</term>
<term>Anti-Dyskinesia Agents (immunology)</term>
<term>Anti-Dyskinesia Agents (therapeutic use)</term>
<term>Antibodies (immunology)</term>
<term>Antibody Formation (drug effects)</term>
<term>Antibody Formation (physiology)</term>
<term>Botulinum Toxins (immunology)</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Electromyography</term>
<term>Enzyme-Linked Immunosorbent Assay (methods)</term>
<term>Humans</term>
<term>Muscles (drug effects)</term>
<term>Reaction Time</term>
<term>Time Factors</term>
<term>Torticollis (drug therapy)</term>
<term>Torticollis (physiopathology)</term>
<term>Treatment Failure</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Antibodies</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Action Potentials</term>
<term>Antibody Formation</term>
<term>Muscles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Enzyme-Linked Immunosorbent Assay</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Antibody Formation</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Electromyography</term>
<term>Humans</term>
<term>Reaction Time</term>
<term>Time Factors</term>
<term>Treatment Failure</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Therapy with botulinum toxin (BT) can fail due to numerous reasons, including failure due to formation of antibodies against BT (BT-AB, AB-TF). AB-TF is a secondary therapy failure, i.e. it occurs during the course of an ongoing BT therapy. It can be subjective or objective, temporary or permanent, and partial or complete. Complete AB-TF is usually preceded by injection series with partial AB-TF in which the therapeutic effect is reduced in its intensity and duration. AB-TF usually occurs within 2 or 3 years after initiation of BT therapy. After 4 years it is rare. BT-AB are neutralising or blocking by definition, i.e. they are directly interfering with BT's biological mechanism of action. Non-neutralizing or non-blocking antibodies occur. BT-AB can be detected by the mouse diaphragm assay, the mouse protection assay, and by patient-based tests such as the sternocleidomastoid test, the extensor digitorum brevis test, and the frowning test. Enzyme-linked immunosorbent assays (ELISA) have a low specificity and a low sensitivity for detection of BT-AB. BT-AB titres drop spontaneously after cessation of BT therapy but latencies are too long to be compatible with an effective BT therapy. BT dosage increase can be successful to overcome AB-TF when AB-TF is partial and when BT-AB titres are low. Usage of alternative BT type A preparations fail to overcome AB-TF. Alternative BT types, such as BT type B and BT type F, are initially successful in AB-TF, but stimulate formation of antibodies against the alternative BT types after few applications. BT-AB reduction with immunosuppressants and inactivation of BT-AB by intravenous immunoglobuline application has not yet been achieved. Extraction of BT-AB by plasmapheresis and immunoadsorption is possible but is associated with substantial logistic problems. Prevention of BT-AB formation, therefore, is of paramount importance. Identified risk factors for BT-AB formation must be taken into account when BT therapy is planned. The most interesting perspective seems to be the development of new BT preparations with reduced antigenicity.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005727 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005727 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:7E1934980910F60F68521285C7890F73746B2F38 |texte= Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |